Sabuwar Shawarwari don Kare Mutane masu Ciwon daji daga COVID-19

Sakin Kyauta | eTurboNews | eTN
Avatar na Linda Hohnholz
Written by Linda Hohnholz

Cibiyar Ciwon Kankara ta Kasa (NCCN) ta buga ingantaccen jagora ga mutanen da ke fama da kansa bisa sabon amincewar FDA da hauhawar kamuwa da cutar COVID-19-akwai a NCCN.org/covid-19.

A yau, National Comprehensive Cancer Network® (NCCN®) ta buga mahimman abubuwan sabuntawa ga shawarwarin ƙwararrun ƙwararrun ƙwararru akan allurar rigakafi da riga-kafi na COVID-19 a cikin mutanen da ke da cutar kansa. Kwamitin Ba da Shawarwari na NCCN kan rigakafin COVID-19 da Prophylaxis Pre-exposure yana haɗuwa akai-akai don yin bitar duk binciken da ake da shi tare da samar da mafi kyawun ayyuka na tushen shaida don kiyaye mutanen da ke fama da cutar kansa a matsayin amintattu kamar yadda zai yiwu yayin bala'in COVID-19. Jagorar da aka sabunta-samuwa a NCCN.org/covid-19-ya haɗa da bayanai kan rigakafin amfani da ƙwayoyin rigakafin ƙwayoyin cuta na ɗan adam ban da waɗannan shugabanni:       

• Marasa lafiya da ke fama da ciwon daji ya kamata su sami cikakken rigakafi, gami da allurai na uku da/ko duk wasu abubuwan ƙarfafawa da aka yarda da su;

• Akwai fifiko mai ƙarfi don rigakafin mRNA;

• Ya kamata a jinkirta yin rigakafin na aƙalla watanni 3 biyo bayan dashen kwayar cutar hematopoietic (HCT) ko ingantacciyar hanyar maganin salula (misali chimeric antigen receptor [CAR] T-cells) don haɓaka ingancin rigakafin. Jinkirin allurar rigakafi a cikin marasa lafiya da ciwon kansa yakamata kuma ya haɗa da waɗanda aka ba da shawarar ga jama'a (misali fallasa kwanan nan ga COVID-19, maganin monoclonal Ab na kwanan nan);

Ana kuma ba da shawarar cikakken rigakafin ga masu kulawa, dangi / abokan hulɗa, da sauran jama'a;

Kwamitin yana ba da cikakken goyon baya ga cikakken umarnin rigakafin ga ma'aikatan kiwon lafiya.

Hukumar Abinci da Magunguna (FDA) ta ba da izinin yin amfani da gaggawa na gaggawa don haɗakar rigakafin ƙwayar cuta ta monoclonal na tixagevimab da cilgavimab don kariya ta riga-kafi daga COVID-19 a cikin manya da yara waɗanda suka fara shekaru 12 (masu nauyi aƙalla 40 kg) waɗanda ke da matsakaici zuwa matsananciyar sulhu na rigakafi kuma maiyuwa ba zai iya amsa allurar ba. Marasa lafiya masu fama da cutar kansar jini (ciki har da waɗanda ke karɓar dashen kwayar halitta ko ingantacciyar maganin salula) suna iya samun isasshen martani ga allurar COVID-19 kuma suna cikin haɗarin manyan rikice-rikice na COVID-19. Kwamitin ya bayyana cewa yana da kyau a ba da fifiko ga waɗannan marasa lafiya don tixagevimab tare da cilgavimab a gaban marasa lafiya da ke da ƙaƙƙarfan ciwon daji a cikin yanayin ƙarancin wadata.

Har ila yau, kwamitin yana goyan bayan shawarwari daga Cibiyar Kula da Cututtuka (CDC), American Society of Transplantation and Cellular Therapy (ASTCT), da American Society of Hematology (ASH) cewa a baya alurar riga kafi ga marasa lafiya da suka kammala dashen kwayar halitta ko injiniyan salula ya kamata su sami maimaita jerin alluran rigakafin farawa daga watanni uku bayan jiyya.

Kwamitin Ba da Shawarwari na NCCN kan rigakafin COVID-19 da rigakafin riga-kafi ya ƙunshi manyan likitocin da yawa daga ko'ina cikin Cibiyoyin Membobin NCCN, waɗanda ke da ƙwarewa ta musamman kan cututtukan cututtuka, haɓaka alluran rigakafi da bayarwa, kula da cutar kansa, da da'a na likitanci. NCCN za ta ci gaba da sabunta shawarwarin don dacewa da canje-canjen yanayi, gami da girmar shaidu.

Ana iya samun duk shawarwarin NCCN don kula da cutar kansa a lokacin bala'in a NCCN.org/covid-19. Ana kuma samun jagorar mai haƙuri da mai kulawa ga alluran rigakafi a NCCN.org/patientguidelines.

Game da marubucin

Avatar na Linda Hohnholz

Linda Hohnholz

Edita a shugaba don eTurboNews bisa ga eTN HQ.

Labarai
Sanarwa na
bako
0 comments
Bayanin Cikin Lissafi
Duba duk maganganu
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...